PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

apperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete # Known.

TRAMPEStitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mpiete if Known		
Application Number	10/802,400		
Filing Date	March 17, 2004		
First Named Inventor	Gerard Marx		
Art Unit	4853 1657		
Examiner Name	Not yet assigned	Wastel	_
Attorney Docket Number	39612/20		_

U. S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where Examiner Cite **Document Number Publication Date** MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials* No. Figures Appear Number-Kind Code² (F known) ^{US-} 6,737,074 B2 05-18-2004 シャ Marx et al. US-US-US US-US US US-US-US-US-US-US. US-US-US-US-US. US-

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
-		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
	1		İ	_		
	2					

Examiner Signature	> M.	WHI -	Date Considered	1/6/	07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspio.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Control number.

Substitute f	or form 1449A	/PTO		Complete if Known					
INIFOR	NA TIO	AL DI	001.001105	Application Number	10/280.871				
			SCLOSURE	Filing Date	October 25, 2002				
STATEMENT BY APPLICANT		APPLICANT	First Named Inventor	Gerard Marx					
lue		baata a		Art Unit	1651 (60 57				
(103	e as many s	neets a.	s necessary)	Examiner Name	Not yet assigned _ Kh				
Sheet	1	lof	3	Attorney Docket Number	20612/12				

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1 2	us- 6,503,731 B2	01-07-2003 11-21-2000	Marx et al.	
	3	us- 5,879,924	03-09-1999	Marx et al. Foster et al.	
	5	us- 5,783,214 us- 5,637,687	07-21-1998	Royer et al. Wiggins	The state of the s
2	6	us- 5,635,609 us- 5,411,885	06-03-1997 05-02-1995	Levy et al.	The state of the s
	8	us- 5,324,647	06-28-1994	Marx et al. Rubens et al.	- distribution and April - The Anticoperate St. 1 is a sign for the Anticoperate St.
an	9 10	us- 5,260,420 us- 5,069,936	11-09-1993 12-03-1991	Burnouf-Fadosevich et al. Yen	**************************************
	11	us- 4,373,027	02-08-1983	Berneman et al.	
an	12	us- 4,147,767 us- 3,937,668	04-03-1979 02-10-1976	Yapel, Jr. Zolle	MINISTER TO COMMUNICATE SAMPLES IN THE SAMPLES WAS A PROSECULAR WAY OF THE PROSECULAR WA
a~	14	us. 6,663,687	05-16-1972	Evans	The second secon
		US-		Mark et al.	
		US-			THE R. LANSING MICHIGAN OF THE PRINCIPLE AND THE
		US-		and the contract of the contra	en an el embero della grap que constitución a la igla apropaga el mantes y
<u>a</u>	15	us. 6,552,172 B2 us. us. us.	04-22-2003	Marx et al.	

		FORE	EIGN PATENT D	OCUMENTS		_
Examiner Initials	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 9 if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
\mathcal{I}	16		01-08-1998	Buford Biomedical, Inc.		6
a	47	Japan 05292899	11-09-1993	Ajinomoto Co., Inc.		F-
سرامسيم	18	WIPO 9404261	08-04-1993	Coletica		-
au	19	WIPO 9404260	03-03-1994	Coletica	and any or production with the product the state	
						-
						-
						┢╌
						-

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04.

The Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

Sindag Main Statement: This form is assignated to take 2.0 hours to complete. The will want depending upon the peace of the individual area.

PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute f	or form 1449B/PTO			Complete if Known		
INIEOE	ACITA NA	DIC	CLOSURE	Application Number	10/280,871	
•				Filing Date	October 25, 2002	
STATEMENT BY APPLICANT				First Named Inventor	Gerard Marx	
		• • •		Group Art Unit	1651 1457	
<u> </u>	(use as many sh	eets a	s necessary)	Examiner Name	Net yet assigned No	
Sheet	2	of	3	Attorney Docket Number	39612/13	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), votume-issue number(s), publisher, city and/or country where published	7
ŽV	20	Lee, et al., Serum Albumin Beads: An Injectable, Biodegradable System for the Sustained Release of Drugs, Science 213:233-235 (1981).	
a	21_	Miyazaki, et al., Preparation and evaluation in Vitro and in Vivo of Fibrinogen Microspheres Containing Adriamycin, Chem Pharm. Bull. (Tokyo), 1986, 34(8): 3384-93.	-
a	22	Arshady, R., Microspheres and Microcapsules: A Survey of Manufacturing Techniques, Part I: Suspension Cross-Linking. Polymer Engineering and Science 29 (24): 1746-1758, 1989.	
a	23	Arshady, R., Microspheres and Microcapsules: A Survey of Manufacturing Techniques: Part II: Coacervation, Polymer Engineering and Science 30 (15): 905-914, 1990.	
w	24	Arshady, R., Microspheres and Microcapsules: A Survey of Manufacturing Techniques: Part III: Solvent Evaporation, Polymer Engineering and Science, 30 (15): 915-924, 1990.	-
ev-	25	Sustick, et al., Protein Microencapsulation of Non-Aqueous Liquids, Journal of American Chemical Society 112:7807-7809, 1990.	
av-	26	Yapel, Albumin Microspheres: Heat and Chemical Stabilization, Methods in Enzymology 112:3-43 (1985).	
zv	27	Ho et al., Fibrin-based delivery systems II. The preparation and characterization of microbeads, Drug Develop. Industrial Pharm. (1994) 20(4): 535-548.	
2	-28	Ho et al., Fibrin-based delivery systems III: The evaluation of the release of macromolecules from microbeads, J. Controlled Release (1995) 34: 65-70.	-
Ju	29	Miyazaki et al., Fibrinogen microspheres as novel drug delivery systems for antitumor drugs, Chem. Pharm. Bull. (1986) 34(3): 1370-75.	
71	30	Dickinson et al., Rheology of milk protein gels and protein-stabilized emulsion gels cross-linked with transglutaminase, J. Agric. Good Chem. (1996) 44:1371-1377.	

	- 11		
Examiner		Date 4/./	
Signature	4 × X /// 1	Considered 1/6/07	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O Box 1450 Alexandria, VA 22313-1450.

^{*}EXAMINER: thitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Control number.

Substitute	for form 1449B/PTO			Co	mplete if Known
INEOE	ORA A TION	n i c	CLOCUDE	Application Number	10/280,871
			CLOSURE	Filing Date	October 25, 2002
STAT	EMENT BY	A	PPLICANT	First Named Inventor	Gerard Marx
				Group Art Unit	1651 (657
	(use as many she	ets a	s necessary)	Examiner Name	Not yet assigned x Cal
Sheet	3	of	3	Attorney Docket Number	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
90	31	Elisha Berman, et al., An Early Transient Increase of Intracellular Na+ may be one of the First Components of the Mitogenic Signal. Direct Detection by 23 Na-NMR Spectroscopy in Quiescent 3T3 Mouse Fibroblasts Stimulated by Growth Factors. Biochimica et Biophysica Acta 1239, (1995), 177-185.	
90	32	Richard I. Senderoff, et al., Fibrin Based Drug Delivery Systems. Journal of Parenteral Science and Technology, vol. 45, No. 1, pp 2-6, Jan/Feb. 1991.	ļ i
			-

THE PROPERTY AND ADMINISTRATION OF THE PARTY AND ADMINISTRATIO			
			,·

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Comissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.